<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03632291</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-A107-IgE</org_study_id>
    <nct_id>NCT03632291</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United BioPharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and
      pharmacodynamics of a single dose of UB-221 as an add-on therapy in patients with Chronic
      Spontaneous Urticaria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, open-label, dose-escalation study to evaluate the safety, tolerability,
      pharmacokinetics, and pharmacodynamics of a single dose of UB-221 as an add-on therapy in
      patients with Chronic Spontaneous Urticaria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event incidence</measure>
    <time_frame>15 days</time_frame>
    <description>from the baseline to day 15 after IP infusion</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Urticaria Chronic</condition>
  <arm_group>
    <arm_group_label>UB-221 (0.2 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-221 (0.6 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-221 (2 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-221 (6 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-221 (10 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-221</intervention_name>
    <description>UB-221 (75 mg/ml)</description>
    <arm_group_label>UB-221 (0.2 mg/kg)</arm_group_label>
    <arm_group_label>UB-221 (0.6 mg/kg)</arm_group_label>
    <arm_group_label>UB-221 (10 mg/kg)</arm_group_label>
    <arm_group_label>UB-221 (2 mg/kg)</arm_group_label>
    <arm_group_label>UB-221 (6 mg/kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with age between 20 to 65 years old (inclusive).

          -  Subjects who are able and willing to provide the informed consent.

          -  Male subjects with body weight of 50 kilogram (kg) or above; female subjects body
             weight of 45 kilogram (kg) or above.

          -  Subjects diagnosed with chronic spontaneous urticaria (CSU).

        Exclusion Criteria:

          -  History of significant diseases (other than CSU) or major clinical conditions by the
             investigator's judgment, such as auto-immune disease or psychiatric and behavioral
             conditions from which the investigator considers the subject is not suitable to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Evelyn Lee</last_name>
    <phone>+886-3-668-4800</phone>
    <phone_ext>3201</phone_ext>
    <email>evelyn.lee@unitedbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Chien</last_name>
    <phone>+886-3-668-4800</phone>
    <phone_ext>3617</phone_ext>
    <email>emily.chien@unitedbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Lee</last_name>
      <phone>886-3-668-4800</phone>
      <phone_ext>3201</phone_ext>
      <email>evelyn.lee@unitedbiopharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UB-221</keyword>
  <keyword>anti-IgE monoclonal antibody</keyword>
  <keyword>chronic spontaneous urticaria (CSU)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

